5,442 results match your criteria Hairy Cell Leukemia


Successful treatment of hairy cell leukemia variant with obinutuzumab.

Ann Hematol 2021 Jun 4. Epub 2021 Jun 4.

Department of Hematology, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

View Article and Full-Text PDF

Preliminary Phytochemical Analysis and Evaluation of the Biological Activity of (L.) R. Br Transformed Roots Extracts Obtained through -Mediated Transformation.

Cells 2021 May 18;10(5). Epub 2021 May 18.

Department of Biology and Pharmaceutical Botany, Medical University of Lodz, 90-151 Lodz, Poland.

According to the present knowledge, this is the first report on establishing transformed root cultures of after -mediated transformation. The preliminary phytochemical analysis showed differences in the content of phenols and flavonoids in transformed and nontransformed roots. The dominant compounds in the analyzed extracts were (+)-catechin (5464 and 6808 µg/g DW), -coumaric acid (2549 and 4907 µg/g DW), -coumaric acid (1508 and 2048 µg/g DW) and rosmarinic acid (1844 and 2643 µg/g DW) for nontransformed (LNNR) and transformed (LNTR4) roots, respectively. Read More

View Article and Full-Text PDF

Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.

Leuk Lymphoma 2021 May 25:1-3. Epub 2021 May 25.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article and Full-Text PDF

[Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?]

Bull Cancer 2021 May 19. Epub 2021 May 19.

CHU d'Angers, service des maladies du sang, 49100 Angers.

Hairy cell leukemia is a rare form of leukemia: three hundred new cases are diagnosed each year in France. The diagnosis is based on: (1) morphological examination of the blood and bone marrow smear, (2) analysis by flow cytometry of hairy cells, which express three or the four following markers: CD11c, CD25, CD103 and CD123, (3) identification of the BRAF mutation, a true molecular marker of the disease. The management of treatment has evolved considerably in recent years. Read More

View Article and Full-Text PDF

Durable Responses with Vemurafenib plus Rituximab in Hairy-Cell Leukemia.

Authors:

Cancer Discov 2021 May 21. Epub 2021 May 21.

Of 30 patients with relapsed or refractory hairy-cell leukemia, 87% experienced complete responses. Read More

View Article and Full-Text PDF

First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival.

Clin Lymphoma Myeloma Leuk 2021 Apr 10. Epub 2021 Apr 10.

Division of Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address:

View Article and Full-Text PDF

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.

N Engl J Med 2021 05;384(19):1810-1823

From the Institute of Hematology, Ospedale S. Maria della Misericordia, and the Department of Medicine, University of Perugia, Perugia (E.T., L.D.C., E.S., M.C., S.A., V.M.P., B.F.), the Department of Medicine, Section of Hematology, University of Verona, Verona (A. Ambrosetti), the Hematology Unit, Ospedale di Cosenza, Cosenza (E.L.), the Hematology Unit, Department of Transfusional Medicine-SIMMT, Maria Paternò-Arezzo Hospital, Ragusa (A. Antolino), the Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome (A.P., R.F.), and the Hematology and Stem Cell Transplant Unit, A.O. San Camillo Forlanini (L.R.), Rome, the Department of Hematology, Spedali Civili di Brescia, Brescia (S.F.), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli" and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (P.L.Z.), the Department of Translational Medicine, Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara (G.G.), the Hematology Unit, Ospedale di Carrara, Carrara (R.D.S.), the Hematology Unit, Ospedale di Frosinone, Frosinone (N.F.), the Hematology Unit, Ospedale di Ronciglione, Viterbo (P.F.), the Hematology Unit, Ospedale di Pesaro, Pesaro (G.V.), and the Hematology Unit, Azienda Sanitaria Universitaria Integrata-Ospedale Maggiore, Trieste (F.Z.) - all in Italy.

Background: Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF V600E kinase-activating mutation plays a pathogenetic role. In clinical trials involving patients with refractory or relapsed HCL, the targeting of BRAF V600E with the oral BRAF inhibitor vemurafenib led to a response in 91% of the patients; 35% of the patients had a complete response. However, the median relapse-free survival was only 9 months after treatment was stopped. Read More

View Article and Full-Text PDF

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.

Leukemia 2021 May 4. Epub 2021 May 4.

Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.

Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. Read More

View Article and Full-Text PDF

The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.

Br J Haematol 2021 May 1. Epub 2021 May 1.

Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

We investigated the current role of interferon-alpha (IFNα) in hairy cell leukaemia (HCL) in a retrospective analysis of patients with HCL. A cohort of 74 patients with HCL was divided in to three groups: (A) patients aged >65 years with first-line treatment; (B) patients with comorbidities with first-line treatment; (C) patients who were purine analogues resistant. In total, 94% achieved a response, with a complete response rate of 24%. Read More

View Article and Full-Text PDF

Plasma cell leukemia morphologically resembling hairy cell leukemia variant.

Int J Lab Hematol 2021 Apr 30. Epub 2021 Apr 30.

Department of Clinical Laboratory, Beijing Lu Daopei Hospital, Beijing, China.

View Article and Full-Text PDF

Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.

Clin Med Insights Cardiol 2021 13;15:11795468211010706. Epub 2021 Apr 13.

Cardiology Department, Sant'Anna Hospital, Como, Italy.

Experience with angiotensin-receptor neprilysin inhibitors (ARNI) in oncologic patients with heart failure (HF) is limited. We report a case of ARNI started as first-choice therapy in a patient with relapsing hairy cell leukaemia (HCL) and HF with depressed left ventricular ejection fraction (LVEF). A middle-aged male, previously treated with rituximab for HCL, was scheduled for cardiologic screening before starting a new antineoplastic therapy for cancer relapse. Read More

View Article and Full-Text PDF

[Clinical features and prognosis of 20 cases of hairy cell leukemia].

Zhonghua Xue Ye Xue Za Zhi 2021 03;42(3):250-252

Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China.

View Article and Full-Text PDF

Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.

Leuk Res 2021 May 30;104:106571. Epub 2021 Mar 30.

Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland. Electronic address:

View Article and Full-Text PDF

Inhibitor of BRAF Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications.

Clin Lymphoma Myeloma Leuk 2021 Mar 3. Epub 2021 Mar 3.

National Research Center for Hematology, Moscow, Russia.

Standard therapy in hairy cell leukemia (HCL) is often impossible at the time of deep neutropenia/agranulocytosis with or without infectious complications; it is thus a complex therapeutic problem. Vemurafenib has been used to treat resistant HCL since 2012. Because vemurafenib does not have a myelotoxic effect, we thought that it could be used to treat HCL associated with deep neutropenia/agranulocytosis with or without the development of infectious complications as a preliminary stage before treatment with cladribine. Read More

View Article and Full-Text PDF

The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas.

Biomedicines 2021 Mar 25;9(4). Epub 2021 Mar 25.

Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15701 Athens, Greece.

Normal B-cell development is a tightly regulated complex procedure, the deregulation of which can lead to lymphomagenesis. One common group of blood cancers is the B-cell non-Hodgkin lymphomas (NHLs), which can be categorized according to the proliferation and spread rate of cancer cells into indolent and aggressive ones. The most frequent indolent B-cell NHLs are follicular lymphoma and marginal zone lymphoma. Read More

View Article and Full-Text PDF

A Case of Histoplasmosis Mimicking Primary Lung Cancer With Liver Metastasis.

Cureus 2021 Feb 23;13(2):e13517. Epub 2021 Feb 23.

Internal Medicine, Sanford Health, University of North Dakota School of Medicine, Fargo, USA.

Histoplasmosis is usually self-limiting in healthy individuals but often fatal in immunocompromised patients. It can mimic primary lung malignancy and liver metastasis, causing a delay in appropriate therapy. We report a case of a 58-year-old male, with a 20 pack-year smoking habit, who presented with a three-week history of persistent fevers and productive cough with night sweats. Read More

View Article and Full-Text PDF
February 2021

Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?

Authors:
Estella Matutes

Expert Rev Hematol 2021 Apr 5;14(4):355-363. Epub 2021 Apr 5.

Hematopathology Unit, Hospital Clinic, Barcelona, Spain.

Introduction: Hairy cell leukemia-variant (HCL-V) is a rare B-cell neoplasm arising or homing primarily in the spleen. It has been considered in the WHO classification of Hemopoietic and Lymphoid Tumors as a provisional entity since 2008 and included under the umbrella of unclassifiable splenomegalic B-cell leukemia/lymphomas. The diagnosis is a challenge to hematopathologists and management of these patients by the clinicians is difficult due to the lack of diagnostic and therapeutic guidelines and prospective studies. Read More

View Article and Full-Text PDF

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.

Blood 2021 Jun;137(25):3473-3483

Division of Hematology and.

Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is highly effective in several malignancies. Its activity in HCL was unknown, so we conducted a multisite phase 2 study of oral ibrutinib in patients with either relapsed classic or variant hairy cell leukemia. Read More

View Article and Full-Text PDF

Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant.

Onco Targets Ther 2021 9;14:1797-1805. Epub 2021 Mar 9.

Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.

Hairy cell leukemia variant (HCL-v) is a rare B-cell lymphoproliferative disorder with distinct immunophenotypic and molecular characteristics when compared to classical hairy cell leukemia (HCL-c). In contrast to the enormous progress in therapeutic options for HCL-c, HCL-v remains a therapeutic challenge due to inferior outcomes with standard chemoimmunotherapy and BCR signaling pathway inhibitors, and due to the fact that HCL-v has limited molecular therapeutic targets. In addition, because of the rarity of the disease, there is a paucity of later phase studies or multicenter trials to guide treatment decisions. Read More

View Article and Full-Text PDF

New developments in non-Hodgkin lymphoid malignancies.

Pathology 2021 Apr 5;53(3):349-366. Epub 2021 Mar 5.

Department of Laboratory Medicine, University of California San Francisco, CA, USA. Electronic address:

The revised fourth edition of the World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues (2017) reflects significant advances in understanding the biology, genetic basis and behaviour of haematopoietic neoplasms. This review focuses on some of the major changes in B-cell and T-cell non-Hodgkin lymphomas in the 2017 WHO and includes more recent updates. The 2017 WHO saw a shift towards conservatism in the classification of precursor lesions of small B-cell lymphomas such as monoclonal B-cell lymphocytosis, in situ follicular and in situ mantle cell neoplasms. Read More

View Article and Full-Text PDF

Lytic Bone Lesion: An Unusual Presentation of Hairy Cell Leukemia.

Cureus 2021 Jan 28;13(1):e12959. Epub 2021 Jan 28.

Hematology/Oncology, St. Joseph's University Medical Center, Paterson, USA.

Hairy cell leukemia (HCL) is a seldom encountered malignancy of lymphocytes with a low incidence in the United States. HCL generally follows an indolent course and not all patients require treatment. Most patients are asymptomatic at the time of diagnosis. Read More

View Article and Full-Text PDF
January 2021

Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis.

Diagn Cytopathol 2021 May 25;49(5):647-656. Epub 2021 Feb 25.

Department of Cytology and Gynecologic Pathology, PGIMER, Chandigarh, India.

Introduction: Involvement of body fluids by lymphoreticular malignancies (LRM) is rare and often associated with poor prognosis and decreased overall survival. The present study was conducted to analyze the characteristic cytomorphologic, flow cytometric and immunocytochemical features of LRMs in serous effusions.

Materials And Methods: This was a three-year retrospective study. Read More

View Article and Full-Text PDF

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.

J Hematol Oncol 2021 Feb 24;14(1):35. Epub 2021 Feb 24.

Developmental Therapeutics Consortium, 175 E Delaware Pl #7204, Chicago, IL, USA.

Background: Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in patients with relapsed/refractory (R/R) hairy cell leukemia (HCL).

Methods: Eligible patients had received ≥ 2 prior systemic therapies, including ≥ 2 purine nucleoside analogs (PNAs), or ≥ 1 PNA followed by rituximab or a BRAF inhibitor. Read More

View Article and Full-Text PDF
February 2021

Massive splenomegaly in hairy cell leukemia causing urinary retention.

Clin Case Rep 2021 Feb 4;9(2):1027-1028. Epub 2020 Dec 4.

Department of Hematology & Oncology Rochester General Hospital Rochester NY USA.

Hairy cell leukemia can cause massive splenomegaly which may lead to urinary retention and constipation. Patients usually require a splenectomy for relief of symptoms. Read More

View Article and Full-Text PDF
February 2021

Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report.

Medicine (Baltimore) 2021 Feb;100(5):e24457

Division of Hematology and Oncology, Toyohashi Municipal Hospital, Aichi.

Introduction: Hairy cell leukemia variant (HCL-v) is a rare lymphoproliferative disorder regarded as a splenic B-cell lymphoma/leukemia, unclassifiable tumor in the 2017 World Health Organization classification of lymphoid tumors. The prognosis of HCL-v is much worse than that of classical hairy cell leukemia and there is no consensus regarding the optimal treatment strategy for HCL-v. For patients with indolent lymphoma, rituximab plus bendamustine (RB) has proven effective in several clinical trials. Read More

View Article and Full-Text PDF
February 2021

Targeted therapy for treatment of patients with classical hairy cell leukemia.

Leuk Res 2021 03 4;102:106522. Epub 2021 Feb 4.

James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States; Department of Medicine, University of Rochester Medical Center, Rochester, NY, United States. Electronic address:

Most patients with treatment naïve classical hairy cell leukemia (cHCL) have durable responses with purine nucleoside analogues. In contrast, options are limited for cHCL patients with co-morbidities, purine analogue intolerance, or resistant disease. We report the utility of targeted therapy for nine cHCL patients presenting with treatment naïve cHCL and severe neutropenia and infection (n = 3), purine analogue intolerance (n = 2), or purine analogue resistant disease (n = 4). Read More

View Article and Full-Text PDF

Treatment-Induced Aggravation of Vasculitis in Hairy-Cell Leukemia.

Clin Lymphoma Myeloma Leuk 2021 May 23;21(5):e429-e431. Epub 2020 Dec 23.

III Department of Medicine, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.

View Article and Full-Text PDF

Massive Splenomegaly and Pancytopenia: It's a Hairy Situation.

Cureus 2020 Dec 23;12(12):e12237. Epub 2020 Dec 23.

Internal Medicine, Emory University School of Medicine, Atlanta, USA.

A 33-year-old previously healthy Middle Eastern male presented to the emergency department with four weeks of progressively worsening fatigue, dyspnea on exertion, night sweats, and a 10-pound weight loss after suffering a self-limiting viral upper respiratory illness. He was found to be profoundly anemic and thrombocytopenic with normal white blood cell count with a lymphocytic predominance. His anemia was refractory to red blood cell transfusions, to which he developed hyperbilirubinemia. Read More

View Article and Full-Text PDF
December 2020